Testing a new DNA vaccine for Alzheimer's disease
Official title: Safety/Tolerability/Immunogenicity of first-in-human Aβ DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA.
Funded at Institute for Molecular Medicine · NIH-11053526 · Data updated 2026-11-12
This study is testing a new DNA vaccine that aims to help your immune system fight a protein linked to Alzheimer's disease, and it's looking for volunteers to see how safe it is and how well it works in creating a protective response.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Institute for Molecular Medicine NIH-funded |
| Lab location | 1 site (Huntington Beach, United States) |
| Project start | February 15, 2022 |
| Project end | January 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $2,288,273 |
| NIH project number | 5R01AG074983-04 |
| Project ID | NIH-11053526 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals in the early stages of Alzheimer's disease who are looking for preventive treatment options.
✕Less likely to help
Patients with advanced Alzheimer's disease or those who do not have any signs of cognitive decline may not benefit from this research.
What this research studies
This research investigates the safety, tolerability, and immune response of a novel DNA vaccine designed to target amyloid-beta, a protein associated with Alzheimer's disease. Participants will receive the vaccine to assess how well it can stimulate the immune system to produce antibodies against amyloid-beta, potentially preventing or slowing the progression of Alzheimer's. The study will involve monitoring participants for any side effects and measuring their immune responses over time. This approach aims to provide a more practical and cost-effective preventive measure compared to existing therapies.
Why it matters
Potential benefit: If successful, this research could lead to a new preventive treatment for Alzheimer's disease that is easier to administer than current therapies.
How similar studies have gone: Previous studies with similar vaccine approaches have shown promise, but this specific DNA vaccine is a novel approach in the field.
Where this research is happening
-
Institute for Molecular Medicine
Huntington Beach, United States Active
Researchers
- Principal investigator: Agadjanyan, Michael G — Institute for Molecular Medicine
- Study coordinator: Agadjanyan, Michael G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.